Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA)

Hsien Tzung Liao, Chun Hsiung Chen, Wei Sheng Chen, Hui Ting Lee, Chang Youh Tsai, Chung Tei Chou

Research output: Contribution to journalArticlepeer-review


Undifferentiated spondyloarthritis (USpA) include incomplete forms or early phases of definite seronegative spondyloarthritis (SpA) and cases of spondyloarthritis that remain undifferentiated. The treatment of SpA is more conditioned by the disease localization. Non-steroidal anti-inflammatory drugs and disease-modifying antirheumatic drugs are the main therapeutic agents for the treatment of peripheral arthritis in USpA. Tumor necrosis factor-α (TNF-α) has been detected in sacroiliac joints of patients with SpA. Anti-TNF-α therapy has been shown efficacious in patients with active ankylosing spondylitis (AS) and psoriatic arthritis. Similar to these SpA subtypes, therapeutic options in USpA are also limited. In those cases in which severe symptoms persist despite these treatments or when there is a severe axial involvement, biologic therapy (such as anti-TNF-α agents) represent an effective choice. In these patients, anti-TNF-α treatment raises the important possibility of blocking a shift from USpA to differentiated forms of spondyloarthritis.

Original languageEnglish
Pages (from-to)174-176
Number of pages3
JournalCurrent Rheumatology Reviews
Issue number3
Publication statusPublished - Aug 2009


  • Tumor necrosis factor-α (TNF-α)
  • Undifferentiated spondyloarthritis (USpA)

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'Anti-tumor necrosis factor-α therapy in undifferentiated spondyloarthritis (USpA)'. Together they form a unique fingerprint.

Cite this